United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 1

Name: Pharmaceutical Preparations Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderVertex Pharmaceuticals · 61

Strongest available pathVertex Pharmaceuticals · +173.4%

Widest latest marginVertex Pharmaceuticals · 32.9%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1VRTX · Nasdaq

Vertex Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1989Boston$137.21B market cap

View full Companies Radar profile

61Moderate

Snapshot price$541.7as of page date

Monthly-close return+173.4%five-year window

FY2025 revenue$12.00BVERTEX PHARMACEUTICALS INC / MA

Net margin32.9%FY2025

P/E snapshot31.5xone ratio, not a verdict

Prism attention1.6%share across these five

Filing track recordRevenue, USD billions

+58.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.2%

52-week position92% through range

$374.2$555.7

News mentions9.8K

Community mentions251partial coverage

U.S.-scope patents62

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal75/100
Management stability90/100
Market position24/100
Capital-event signal80/100
Innovation pulse22/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 6 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ABBV · NYSE

AbbVie

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2013North Chicago, Illinois$451.46B market cap

View full Companies Radar profile

60Moderate

Snapshot price$255.5as of page date

Monthly-close return+113.7%five-year window

FY2025 revenue$61.16BAbbVie Inc.

Net margin6.9%FY2025

P/E snapshot72.0xone ratio, not a verdict

Prism attention5.8%share across these five

Filing track recordRevenue, USD billions

+8.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%

52-week position84% through range

$190.8$267.5

News mentions34.8K

Community mentions5.9Kpartial coverage

U.S.-scope patents9278

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal51/100
Management stability90/100
Market position53/100
Capital-event signal89/100
Innovation pulse27/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 93 M&A involvements, 20 asset-acquisition events and 30 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3JNJ · NYSE

Johnson & Johnson

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1930Charleston, South Carolina$645.95B market cap

View full Companies Radar profile

55Moderate

Snapshot price$268.0as of page date

Monthly-close return+53.5%five-year window

FY2025 revenue$94.19BJOHNSON & JOHNSON

Net margin28.5%FY2025

P/E snapshot31.1xone ratio, not a verdict

Prism attention24.6%share across these five

Filing track recordRevenue, USD billions

+0.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.1%

52-week position92% through range

$173.3$276.5

News mentions146.7K

Community mentions1.0Kpartial coverage

U.S.-scope patents18790

Prism InsightsWhat sits behind the readiness signal
Observed risk 17/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position36/100
Capital-event signal76/100
Innovation pulse27/100

Management signal

No leadership-churn flag in the model; 8 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 197 M&A involvements, 49 asset-acquisition events and 55 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

Recent available records contain 7 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4REGN · Nasdaq

Regeneron Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2020Tarrytown, New York$81.77B market cap

View full Companies Radar profile

52Moderate

Snapshot price$794.2as of page date

Monthly-close return+19.9%five-year window

FY2025 revenue$14.34BREGENERON PHARMACEUTICALS, INC.

Net margin31.4%FY2025

P/E snapshot19.6xone ratio, not a verdict

Prism attention2.1%share across these five

Filing track recordRevenue, USD billions

-10.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.8%

52-week position83% through range

$541.0$847.0

News mentions12.8K

Community mentions165partial coverage

U.S.-scope patents49

Prism InsightsWhat sits behind the readiness signal
Observed risk 13/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position47/100
Capital-event signal55/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 24 M&A involvements, 12 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 3 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5PFE · NYSE

Pfizer

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2004WILMINGTON$159.36B market cap

View full Companies Radar profile

35Cautious

Snapshot price$27.96as of page date

Monthly-close return-39.2%five-year window

FY2023 revenue$50.91BPFIZER INC

Net margin4.2%FY2023

P/E snapshot36.8xone ratio, not a verdict

Prism attention65.9%share across these five

Filing track recordRevenue, USD billions

-5.1%

FY2018–FY2023 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -1.3%

52-week position85% through range

$23.58$28.75

News mentions392.6K

Community mentions62.7Kpartial coverage

U.S.-scope patents23441

Prism InsightsWhat sits behind the readiness signal
Observed risk 36/100higher means more observed risk

Earnings signal22/100
Management stability90/100
Market position63/100
Capital-event signal65/100
Innovation pulse24/100

Management signal

No leadership-churn flag in the model; 15 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 331 M&A involvements, 129 asset-acquisition events and 169 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

Recent available records contain 24 lawsuit, 1 regulatory and 2 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Vertex Pharmaceuticals

+173.4%

AbbVie

+113.7%

Johnson & Johnson

+53.5%

Regeneron Pharmaceuticals

+19.9%

Pfizer

-39.2%

Latest revenue

USD billions, official filing scope shown on each company card.

Johnson & Johnson

$94.19B

AbbVie

$61.16B

Pfizer

$50.91B

Regeneron Pharmaceuticals

$14.34B

Vertex Pharmaceuticals

$12.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Vertex Pharmaceuticals

32.9%

Regeneron Pharmaceuticals

31.4%

Johnson & Johnson

28.5%

AbbVie

6.9%

Pfizer

4.2%

Prism news attention

Normalized share across these five names; attention is not quality.

Pfizer

65.9%

Johnson & Johnson

24.6%

AbbVie

5.8%

Regeneron Pharmaceuticals

2.1%

Vertex Pharmaceuticals

1.6%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Pfizer leads the conversation

It holds 65.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $50.91B.

Price path

Vertex Pharmaceuticals leads the available price paths

Its monthly-close return is +173.4% for the five-year window. At the other end, Pfizer is -39.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Vertex Pharmaceuticals has the widest latest margin

Its FY2025 net margin is 32.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Regeneron Pharmaceuticals shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 19.6x while its five-year window price return is +19.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · VRTX

Vertex Pharmaceuticals

9,834available Prism news records

Prism top themes

Price action & investor response

441

Capital allocation & transactions

223

Macro demand & rates

187

Earnings & financial performance

144

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.9%1,529 latest 12m vs 1,558 prior 12m

Machine-classified coverage tone

91.2% positive+6.6 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 274crispr-cas9 212crispr applications 194stock performance 128cell-based therapies 100rare disease clinical trials 95stem cell banking 88non-opioid analgesics 85

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-01 · trend and themes shown through 2026-08

Areas of research · ABBV

AbbVie

34,821available Prism news records

Prism top themes

Price action & investor response

1,565

Capital allocation & transactions

583

Legal, arbitration & regulatory

574

Earnings & financial performance

561

Macro demand & rates

356

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+13.6%5,525 latest 12m vs 4,862 prior 12m

Machine-classified coverage tone

87.4% positive+2.2 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 319stock performance 186orphan drug pricing 152angiogenesis inhibitors 146earnings report 137adc therapeutics 133stock price 133private equity 116

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-12 · trend and themes shown through 2026-07

Areas of research · JNJ

Johnson & Johnson

146,691available Prism news records

Prism top themes

Price action & investor response

2,563

Macro demand & rates

1,865

Capital allocation & transactions

876

Leadership & governance

823

Earnings & financial performance

639

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-33.9%9,484 latest 12m vs 14,347 prior 12m

Machine-classified coverage tone

80.3% positive+6.8 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine candidates 1,046vaccine trials 906vaccination campaigns 884mass vaccination sites 745vaccine immunogenicity 720covid-19 vaccine development 612pandemic vaccine stockpiling 597pandemic vaccine deployment 586

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-03 · trend and themes shown through 2026-08

Areas of research · REGN

Regeneron Pharmaceuticals

12,792available Prism news records

Prism top themes

Legal, arbitration & regulatory

231

Price action & investor response

226

Capital allocation & transactions

186

Earnings & financial performance

134

Macro demand & rates

134

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+22.0%1,799 latest 12m vs 1,474 prior 12m

Machine-classified coverage tone

78.6% positive+5.3 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 157generic drug approval 101copyright duration 99copyright assignment 99copyright fair use 99copyright enforcement 99copyright remedies 99brand protection programs 95

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-07-09 · trend and themes shown through 2026-07

Areas of research · PFE

Pfizer

392,601available Prism news records

Prism top themes

Macro demand & rates

1,780

Price action & investor response

1,568

Capital allocation & transactions

1,282

Earnings & financial performance

891

Legal, arbitration & regulatory

842

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-40.2%15,248 latest 12m vs 25,489 prior 12m

Machine-classified coverage tone

71.5% positive+5.3 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine candidates 5,748vaccine trials 5,526vaccine immunogenicity 4,762vaccination campaigns 4,638mass vaccination sites 3,204vaccination coverage 2,361vaccine effectiveness study 2,234vaccine durability 2,043

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-04 · trend and themes shown through 2026-08

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

VRTX

Vertex Pharmaceuticals

251 mentions

Stock and valuation

109

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 251 records remained after filtering.

ABBV

AbbVie

5,881 mentions

Products, pricing and logistics

2,224

Stock and valuation

1,354

Workplace and hiring

219

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 5,881 records remained after filtering.

JNJ

Johnson & Johnson

1,013 mentions

Stock and valuation

255

Products, pricing and logistics

251

Workplace and hiring

125

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,013 records remained after filtering.

REGN

Regeneron Pharmaceuticals

165 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 165 records remained after filtering.

PFE

Pfizer

62,666 mentions

Products, pricing and logistics

19,179

Stock and valuation

14,974

Workplace and hiring

1,763

Other company context

182

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 62,666 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

VRTX

Vertex Pharmaceuticals

through 2026-05-05

Earnings releases 48Leadership changes 19Company announcements 11M&A 5Business contracts 4

2026-05-05
Earnings releases
Chief Operating Officer and Chief Financial Officer Charlie Wagner said total revenue rose 8% year over year to $2.99 billion, with non‑GAAP EPS was $4.47 compared with $4.06 in the prior‑year quarter.
2026-04-17
Board updates
termination of Mr. Upadhyay's service on our board of directors
2026-01-12
Company announcements
Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ABBV

AbbVie

through 2026-04-17

Earnings releases 79M&A 38Leadership changes 19Lawsuits 17Business contracts 15

2026-04-17
Earnings releases
AbbVie increased its revenue over 8% to $61 billion for the year.
2026-04-16
Lawsuits
The Seventh Circuit affirmed the dismissal of a False Claims Act (FCA) retaliation suit against AbbVie Inc. (formerly Allergan) brought by former sales representative Jeffrey Lewis.
2026-04-15
Company announcements
AbbVie announced on Monday (13), in São Paulo, the expansion of its investment in clinical research in Brazil.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

JNJ

Johnson & Johnson

through 2026-04-30

Lawsuits 177Earnings releases 96M&A 59Leadership changes 39Company announcements 30

2026-04-30
Leadership changes
Johnson & Johnson (NYSE: JNJ ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026.
2026-04-15
Earnings releases
The company reported Q1 sales growth of 9.9 percent year-over-year to $24.1 billion, with operational growth of 6.4 percent and adjusted operational growth of 5.3 percent.
2026-02-03
Lawsuits
Fortis Advisors, representing Auris Health’s former stockholders, sued J&J, claiming it failed to honor its contractual obligations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

REGN

Regeneron Pharmaceuticals

through 2026-04-30

Earnings releases 49Lawsuits 32Leadership changes 18Asset acquisitions 12Company announcements 12

2026-04-30
Earnings releases
Regeneron Pharmaceuticals has reported GAAP net income of $727m for the first quarter of 2026 (Q1 2026), down 10% from $809m in Q1 2025.
2026-04-23
M&A
Franklin Resources Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 6.0% in the 3rd quarter.
2026-04-13
Business contracts
On Monday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced a deal with Melbourne-based Telix Pharmaceuticals Ltd. (ASX:TLX; NASDAQ:TLX) to co-develop and co-commercialize four programs, with options to add four more.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PFE

Pfizer

through 2026-04-29

Earnings releases 111M&A 75Company announcements 68Business contracts 67Lawsuits 54

2026-04-29
Lawsuits
The settlements, which end lawsuits filed by Pfizer alleging patent infringement, push back the US patent expiry for Vyndamax to 2031.
2026-04-28
Asset acquisitions
Jamjoom Pharma, a leading pharmaceutical company in the Middle East and Africa (MEA), today announced the signing of a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility located in King Abdullah Economic City (KAEC), Saudi Arabia.
2026-04-20
Leadership changes
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according to an analyst note on Monday.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Vertex Pharmaceuticals leads the readiness ranking

Its Prism readiness score is 61/100, the highest in this five-company comparison.

Open Vertex Pharmaceuticals in Companies Radar

Scale and margin leadership sit with Johnson & Johnson and Vertex Pharmaceuticals

Johnson & Johnson has the largest displayed latest revenue at $94.19B; Vertex Pharmaceuticals has the widest displayed latest margin at 32.9%.

Open Johnson & Johnson in Companies Radar Open Vertex Pharmaceuticals in Companies Radar

Comparisons

Strongest versus weakest available price path

Vertex Pharmaceuticals is +173.4% for its five-year window; Pfizer is -39.2% for its five-year window.

Open Vertex Pharmaceuticals in Companies Radar Open Pfizer in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $94.19B for Johnson & Johnson to $12.00B for Vertex Pharmaceuticals. Entity and filing-period labels remain visible on the company cards.

Open Johnson & Johnson in Companies Radar Open Vertex Pharmaceuticals in Companies Radar

Anomalies

Pfizer has the widest attention-readiness rank gap

It ranks #1 by measured news attention (65.9%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Pfizer in Companies Radar

Regeneron Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is -10.8% while its available monthly-close return is +19.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Regeneron Pharmaceuticals in Companies Radar

Explanations

Attention measures coverage volume, not quality

Pfizer's 65.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Pfizer in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Vertex Pharmaceuticals's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 61/100 score.

Open Vertex Pharmaceuticals in Companies Radar

Stress-test the largest divergence before forming a view

Compare Regeneron Pharmaceuticals's profile with Vertex Pharmaceuticals's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Regeneron Pharmaceuticals in Companies Radar Open Vertex Pharmaceuticals in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.